» Articles » PMID: 19465903

Characterization of ETS Gene Aberrations in Select Histologic Variants of Prostate Carcinoma

Overview
Journal Mod Pathol
Specialty Pathology
Date 2009 May 26
PMID 19465903
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma. These variants often differ from the latter in clinical, immunophenotypic, and biologic potential. Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas. However, the frequency and significance of this critical molecular event is unknown in the histologic variants of prostate carcinoma. Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7). A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated. Overall, 55% of histologic variant or variation morphologies demonstrated ETS aberrations (ERG in 54% and ETV1 in 1%). TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively. Previously, we reported that 100% of androgen-independent metastatic prostate carcinomas harboring TMPRSS2:ERG gene fusion were associated with interstitial deletion (Edel). Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype. SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma. Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter. Overall, our data provide insight into the origin, molecular mechanism, and phenotypic association of ETS fusions in histologic variants of prostate carcinoma.

Citing Articles

Molecular events in neuroendocrine prostate cancer development.

Wang Y, Wang Y, Ci X, Choi S, Crea F, Lin D Nat Rev Urol. 2021; 18(10):581-596.

PMID: 34290447 PMC: 10802813. DOI: 10.1038/s41585-021-00490-0.


Optimizing the diagnosis and management of ductal prostate cancer.

Ranasinghe W, Shapiro D, Zhang M, Bathala T, Navone N, Thompson T Nat Rev Urol. 2021; 18(6):337-358.

PMID: 33824525 DOI: 10.1038/s41585-021-00447-3.


Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation.

Zhang Y, Shen H, Liao K, Wu W, Li J, Yu H Front Oncol. 2021; 10:504381.

PMID: 33425711 PMC: 7786235. DOI: 10.3389/fonc.2020.504381.


High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.

Zeinali M, Lee M, Nadhan A, Mathur A, Hedman C, Lin E Cancers (Basel). 2020; 12(1).

PMID: 31947893 PMC: 7016759. DOI: 10.3390/cancers12010127.


Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Testa U, Castelli G, Pelosi E Medicines (Basel). 2019; 6(3).

PMID: 31366128 PMC: 6789661. DOI: 10.3390/medicines6030082.


References
1.
Lakhani S . The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res. 2001; 1(1):31-5. PMC: 138498. DOI: 10.1186/bcr10. View

2.
Mehra R, Tomlins S, Shen R, Nadeem O, Wang L, Wei J . Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007; 20(5):538-44. DOI: 10.1038/modpathol.3800769. View

3.
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur S . TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26(31):4596-9. DOI: 10.1038/sj.onc.1210237. View

4.
Randolph T, Amin M, Ro J, Ayala A . Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol. 1997; 10(6):612-29. View

5.
Nam R, Sugar L, Yang W, Srivastava S, Klotz L, Yang L . Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007; 97(12):1690-5. PMC: 2360284. DOI: 10.1038/sj.bjc.6604054. View